Cognitive behavioral therapy for suicide prevention in youth admitted to hospital following an episode of self-harm: A pilot randomized controlled trial.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 04 2020
Historique:
received: 07 10 2019
revised: 29 11 2019
accepted: 28 01 2020
pubmed: 15 2 2020
medline: 16 2 2021
entrez: 15 2 2020
Statut: ppublish

Résumé

Self-harm (SH) is among the strongest risk factors for eventual suicide death yet there are limited data on which interventions are most effective for treating SH in youth. This single-blind, pilot randomized controlled trial examined brief cognitive behavioral therapy (BCBT) for suicide prevention vs. minimally-directive supportive psychotherapy in youth (aged 16-26) hospitalized following SH. Both therapies included 10 acute sessions over 15 weeks with three booster sessions occurring at three month intervals thereafter. The primary feasibility outcome was ≥70% retention at study endpoint. Efficacy measures, including repeat SH, were secondary outcomes. Twenty-four subjects were enrolled (12 per group) with one BCBT subject and two controls dropping out prior to the first therapy session. Five (45%) of the remaining BCBT subjects and seven (70%) control subjects completed all 10 acute therapy sessions. All subjects who completed five sessions went on to complete 10. There were significantly fewer instances of repeat SH in BCBT subjects (7 of 62 weeks of acute follow-up; 11%) compared to control subjects (24 of 79 weeks; 30%)(OR 0.34, 95%CI:0.13-0.92). Three subjects, all in the control condition, made a total of five suicide attempts during the study. This study had a modest sample size and retention rate. This study failed to achieve its primary feasibility retention goal for BCBT. However, it did demonstrate that initial adherence to follow-up predicted study completion. Despite small numbers, it also found a significant reduction in repeat SH in the BCBT group, a finding which requires replication.

Sections du résumé

BACKGROUND
Self-harm (SH) is among the strongest risk factors for eventual suicide death yet there are limited data on which interventions are most effective for treating SH in youth.
METHODS
This single-blind, pilot randomized controlled trial examined brief cognitive behavioral therapy (BCBT) for suicide prevention vs. minimally-directive supportive psychotherapy in youth (aged 16-26) hospitalized following SH. Both therapies included 10 acute sessions over 15 weeks with three booster sessions occurring at three month intervals thereafter. The primary feasibility outcome was ≥70% retention at study endpoint. Efficacy measures, including repeat SH, were secondary outcomes.
RESULTS
Twenty-four subjects were enrolled (12 per group) with one BCBT subject and two controls dropping out prior to the first therapy session. Five (45%) of the remaining BCBT subjects and seven (70%) control subjects completed all 10 acute therapy sessions. All subjects who completed five sessions went on to complete 10. There were significantly fewer instances of repeat SH in BCBT subjects (7 of 62 weeks of acute follow-up; 11%) compared to control subjects (24 of 79 weeks; 30%)(OR 0.34, 95%CI:0.13-0.92). Three subjects, all in the control condition, made a total of five suicide attempts during the study.
LIMITATIONS
This study had a modest sample size and retention rate.
CONCLUSIONS
This study failed to achieve its primary feasibility retention goal for BCBT. However, it did demonstrate that initial adherence to follow-up predicted study completion. Despite small numbers, it also found a significant reduction in repeat SH in the BCBT group, a finding which requires replication.

Identifiants

pubmed: 32056945
pii: S0165-0327(19)32735-1
doi: 10.1016/j.jad.2020.01.178
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

686-694

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All authors report no financial relationships with commercial interests of relevance to this study. Dr. Sinyor reports that he has received grant support from the Innovation Fund of the Alternative Funding Plan from the Academic Health Sciences Centres of Ontario, the American Foundation for Suicide Prevention, the Ontario Ministry of Research and Innovation, and the University of Toronto, Department of Psychiatry Excellence Fund. Dr. Bryan reports that he has received grant support from the Department of Defense, Department of the Air Force, National Institute of Mental Health, Bob Woodruff Foundation, and the Boeing company; and consulting fees from Oui Therapeutics and Neurostat Analytical Solutions.

Auteurs

Mark Sinyor (M)

Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada. Electronic address: mark.sinyor@sunnybrook.ca.

Marissa Williams (M)

Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Athabasca University, Athabasca, AB, Canada.

Rachel Mitchell (R)

Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada.

Rabia Zaheer (R)

Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; University of Waterloo, Waterloo, Canada.

Craig J Bryan (CJ)

National Center for Veterans Studies, Salt Lake City, Utah, United States; Department of Psychology, University of Utah, Utah, United States.

Ayal Schaffer (A)

Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada.

Neal Westreich (N)

Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada.

Janet Ellis (J)

Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada.

Benjamin I Goldstein (BI)

Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada.

Amy H Cheung (AH)

Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada.

Steven Selchen (S)

Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada.

Alex Kiss (A)

Evaluative Clinical Sciences, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada; Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.

Homer Tien (H)

Evaluative Clinical Sciences, Tory Trauma Program, Sunnybrook Research Institute, Toronto, Canada; Department of General Surgery, Faculty of Medicine, University of Toronto, Toronto, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH